TY - JOUR T1 - Medicinal marijuana use: experiences of people with multiple sclerosis. JF - Canadian Family Physician JO - Can Fam Physician SP - 64 LP - 65 VL - 52 IS - 1 AU - Stacey A Page AU - Marja J Verhoef Y1 - 2006/01/01 UR - http://www.cfp.ca/content/52/1/64.abstract N2 - OBJECTIVE To describe medical marijuana use from the perspectives of patients with multiple sclerosis. DESIGN A qualitative, descriptive design was used. Participants discussed their medicinal marijuana use in one-to-one, semistructured interviews. SETTING Interviews were conducted at a time and place convenient to participants. PARTICIPANTS Six men and eight women with multiple sclerosis participated. METHOD Potential participants identified themselves to the researcher after receiving an invitation in a mailed survey. Eligibility was confirmed, and purposive sampling was used to recruit subjects. A range of issues emerged from the interviews. Interviews and data analysis continued until saturation occurred. MAIN FINDINGS Descriptions fell into three broad areas: patterns of use, legal or social concerns, and perceived effects. Consumption patterns ranged from very infrequent to very regular and were influenced by symptoms, social factors, and supply. Legal concerns expressed by most respondents were negligible. Social concerns centred on to whom use was revealed. The perceived benefits of use were consistent with previous reports in the literature: reduction in pain, spasms, tremors, nausea, numbness, sleep problems, bladder and bowel problems, and fatigue and improved mood, ability to eat and drink, ability to write, and sexual functioning. Adverse effects included problems with cognition, balance, and fatigue and the feeling of being high. Although participants described risks associated with using marijuana, the benefits they derived made the risks acceptable. CONCLUSION Further research is needed to clarify the safety and efficacy of marijuana use by patients with multiple sclerosis. If evidence of benefit is seen, medicinal marijuana should be made available to patients who could benefit from it. Until then, discussing medicinal marijuana use with patients will be awkward for health professionals. ER -